Electric Tubular Anastomosis in Rectal Cancer

Sponsor
LI XIN-XIANG (Other)
Overall Status
Completed
CT.gov ID
NCT05879172
Collaborator
(none)
400
1
2
21
19.1

Study Details

Study Description

Brief Summary

Compared with traditional manual suturing, mechanical anastomosis can reduce the error caused by human factors. The electric anastomotic device can improve the automation and accuracy of anastomosis, reduce the requirements for doctors' operation, and establish a more standardized usage specification, thereby reducing the surgical complication rate and improving the quality of anastomosis. The clinical study of electric tubular anastomotic device adopts a multicenter, randomized, parallel controlled non-inferior study design, and randomly groups according to the 1:1 ratio to evaluate the clinical effectiveness and safety of electric tubular anastomotic device compared with conventional manual device.

Condition or Disease Intervention/Treatment Phase
  • Device: electric tubular anastomotic device
  • Device: traditional anastomotic device
N/A

Detailed Description

Compared with traditional manual suturing, mechanical anastomosis can reduce the error caused by human factors, involving the advantages like simple operation, short operation time, fast postoperative recovery, etc. Mechanical anastomosis can also ensure the consistency and repeatability of the surgical anastomosis process. The electric anastomotic device can improve the automation and accuracy of anastomosis, reduce the requirements for doctors' operation, and establish a more standardized usage specification, thereby reducing the surgical complication rate and improving the quality of anastomosis.

The clinical study of electric tubular anastomotic device adopts a multicenter, randomized, parallel controlled non-inferior study design, and randomly groups according to the 1:1 ratio to evaluate the clinical effectiveness and safety of electric tubular anastomotic device compared with conventional manual device.

The effectiveness of the electric tubular anastomotic device was evaluated by taking the success rate of anastomosis and anastomosis-related adverse events as the main evaluation indexes, while the operation performance evaluation, operation time, anastomosis time and postoperative recovery as the secondary evaluation indicators. The safety of electric tubular anastomotic device was evaluated by adverse events, vital signs, laboratory tests, etc.

Study Design

Study Type:
Interventional
Actual Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Application of Electric Tubular Anastomotic Device in Colorectal Tumor Surgery: a Multi-center Clinical Trial
Actual Study Start Date :
Jul 1, 2021
Actual Primary Completion Date :
Jul 31, 2022
Actual Study Completion Date :
Mar 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: traditional anastomotic device

Device: traditional anastomotic device
Traditional anastomosis is used in this group. Staplers of the same brand are uniformly adopted to avoid differences between groups caused by different brands.

Experimental: electric tubular anastomotic device

Device: electric tubular anastomotic device
The electric tubular anastomotic device developed by Suzhou Yingtukang Medical Technology Co., Ltd. is used for colorectal end-to-end and end-to-side anastomosis. This product is suitable for open or minimally invasive colorectal cancer surgery. Before firing the device, tissue thickness should be carefully assessed to prevent poor staling leading to leakage, inadequate hemostasis, or poor treatment.

Outcome Measures

Primary Outcome Measures

  1. success rate of anastomosis [1 week after surgery]

    The end-to-end and end-to-side anastomosis of the intestinal tissue is performed during the operation. After the performance of anastomosis, the instrument is withdrawn. The anastomosis should be checked of accuracy, completeness and bleeding.

Secondary Outcome Measures

  1. time period of anastomosis [during the operation]

  2. time period of recovery [1 year after surgey]

    time of first postoperative defecation or exhausting

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age: 18-80y;

  • Patients with resectable rectal cancer who are scheduled to undergo Dixon surgery (definition of rectal cancer: the lower boundary of the tumor is 10 cm from the anus≤);

  • The patient consents to participate in the clinical study and signs the informed consent form.

Exclusion Criteria:
  • Patients with significant local or systemic severe infection;

  • Acute abdomen: intestinal obstruction, peritonitis, intestinal perforation;

  • Have a systemic underlying disease that has not been controlled, or is unstable; Patients with poor constitution or serious other organic diseases who cannot tolerate anesthesia and surgery;

  • Women during pregnancy, perinatal and lactation;

  • Patients who are mentally incapable or unable to understand the requirements of the study;

  • Patients who participated in other clinical studies 6 weeks before the start of this study or at the same time;

  • The life expectancy of patients with malignant tumors is less than 6 months;

  • Those who are critically ill and find it difficult to make an accurate evaluation of the effectiveness and safety of the device;

  • Patients with diseases who are believed not suitable to participate in this clinical study;

  • Have other diseases that are against anastomosis;

  • The patient is receiving hormone therapy or immunosuppressive therapy;

  • Albumin< 30g/dl.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fudan University Shanghai Cancer Center Shanghai Shanghai China 200032

Sponsors and Collaborators

  • LI XIN-XIANG

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
LI XIN-XIANG, Professor, Fudan University
ClinicalTrials.gov Identifier:
NCT05879172
Other Study ID Numbers:
  • FDCRC71-LXX
First Posted:
May 30, 2023
Last Update Posted:
May 30, 2023
Last Verified:
May 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by LI XIN-XIANG, Professor, Fudan University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 30, 2023